CVac, short for ‘Cancer Vaccine’, is a potential immunotherapeutic agent that developed in Australia. CVac works by attaching an adjuvant, mannan, to the tumor cell surface protein MUC1, a glycoprotein commonly expressed on a variety of cancers. CVac is often compared to the immunotherapeutic agent Provenge, which gained FDA approval in 2010.
CVac was developed by the biotechnology company Prima BioMed ( Nasdaq: PBMD) through to Phase II clinical studies between 2001 and 2015. After inconclusive clinical data in ovarian cancer 2013 and 2014, Prima announced in February 2015 that it had ceased recruiting into CVAc clinical studies and was seeking commercial partners for the product. Evidence from the CAN-003 Phase IIb study has suggested that the product may have utility in ovarian cancer patients in their second remission.